WHAT WE'RE READING

989 A Sampling of Highlights from the Literature

CANCER IMMUNOLOGY AT THE CROSSROADS

Jonathan A. Trujillo, Randy F. Sweis, Riyue Bao, and Jason J. Luke

CANCER IMMUNOLOGY MINIATURES

1001 Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Jeremy Lewin, Scott Davidson, Nathaniel D. Anderson, Beatrice Y. Lau, Jacalyn Kelly, Uri Tabori, Samer Salah, Marcus O. Butler, Kyaw L. Aung, Adam Shlief, Brendan C. Dickson, and Albiurini R. Abdul Razak

1008 Siglec-6 on Chronic Lymphocytic Leukemia Cells Is a Target for Post-Allogeneic Hematopoietic Stem Cell Transplantation Antibodies
Jing Chang, Haiyong Peng, Brian C. Shaffer, Sivasubramanian Baskar, Ina C. Wecken, Matthew G. Cyr, Gustavo J. Martinez, Jo Soden, Jim Freeth, Adrian Wiestner, and Christoph Rader

1014 IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer
Bhalchandra Mirlekar, Daniel Michaud, Ryan Searcy, Kevin Greene, and Yuliyu Palyeya-Gupta

1025 Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

1039 Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
J. Bryan Iorgulescu, Maya Harary, Cheryl K. Zogg, Keith L. Ligon, David A. Reardon, F. Stephen Hodi, Ayal A. Aizer, and Timothy R. Smith

1046 Circulating Tumor Microparticles Promote Lung Metastasis by Reprogramming Inflammatory and Mechanical Niches via a Macrophage-Dependent Pathway
Huaifeng Zhang, Yuandong Yu, Li Zhou, Jingwei Ma, Jiadi Lv, Wenguang Dong, Tianzhen Zhang, Degaoy Chen, Jing Xie, Yuying Liu, and Bo Huang

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org
Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigen to CD8⁺ T Cells

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4⁺ Foxp3⁺ Cell–Mediated Modulation of CD103⁺ Dendritic Cells

RO8t-Expressing Tregs Drive the Growth of Colitis-Associated Colorectal Cancer by Controlling IL6 in Dendritic Cells

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia

ABOUT THE COVER

Although immunotherapy has shown success in treating a variety of cancers, patients with pancreatic ductal adenocarcinoma (PDA) remain unresponsive to treatment, and the lack of efficient antitumor responses is not yet well understood. Mitigakar et al. establish IL35 as a driver of PDA tumor growth via suppression of T cell–mediated responses. Comparison of mice with and without this cytokine show that IL35’s absence significantly reduces pancreatic tumor growth, increases tumor infiltration by CD8⁺ T cells, and improves anti-PD-1 efficacy. Thus, IL35 is a cytokine that may be targeted to improve antitumor responses in PDA, including responses to PD-1 blockade. Read more in this issue starting on page 1014.